Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023;21(7):1504-1518.
doi: 10.2174/1570159X21666221208091805.

KCa-Related Neurological Disorders: Phenotypic Spectrum and Therapeutic Indications

Affiliations
Review

KCa-Related Neurological Disorders: Phenotypic Spectrum and Therapeutic Indications

Aqeela Zahra et al. Curr Neuropharmacol. 2023.

Abstract

Although potassium channelopathies have been linked to a wide range of neurological conditions, the underlying pathogenic mechanism is not always clear, and a systematic summary of clinical manifestation is absent. Several neurological disorders have been associated with alterations of calcium-activated potassium channels (KCa channels), such as loss- or gain-of-function mutations, post-transcriptional modification, etc. Here, we outlined the current understanding of the molecular and cellular properties of three subtypes of KCa channels, including big conductance KCa channels (BK), small conductance KCa channels (SK), and the intermediate conductance KCa channels (IK). Next, we comprehensively reviewed the loss- or gain-of-function mutations of each KCa channel and described the corresponding mutation sites in specific diseases to broaden the phenotypic-genotypic spectrum of KCa-related neurological disorders. Moreover, we reviewed the current pharmaceutical strategies targeting KCa channels in KCa-related neurological disorders to provide new directions for drug discovery in anti-seizure medication.

Keywords: Potassium channels; action potential; channelopathies; epilepsy; modulators; pharmacology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Fig. (1)
Fig. (1)
A topography of the BK channel with reported human mutation sites. (A) Each α-subunit of the BK channel has seven transmembrane domains (S0~S6), with the pore area between S5 and S6. A functional channel is made up of four of these subunits, with the C-terminus being one of the longest of all potassium channels. The C-terminus comprises two regulators of potassium conductance (RCK) domains, RCK1, and RCK2, which stack on top of one another to create a gating ring beneath the channel opening pore. (B) A single BK channel cry-EM subunit (PDB entry: 6V38). S0-S6 denote the transmembrane segments; Selectivity filter (SF) denotes the selectivity property; the two Ca2+ molecules that are coupled to the channel are represented in yellow. (C) GOF mutation sites are shown in blue, LOF mutation sites are in red mapped onto the BK channel structure and Ca2+ ions bound to the channel are shown in yellow circles. (B and C Copyright from 2022 [Jianmin Cui]. All Rights Reserved) [15].
Fig. (2)
Fig. (2)
A topography of the SK channel with reported human mutation sites. SK channel has six transmembrane domains (S1~S6), with the pore region between S5 and S6. Both the N-terminus and the C-terminus point toward the cytoplasm. The CaM binding site, protein kinase CK2 and protein phosphatase (PPP) binding sites are indicated by yellow, pink, and purple, respectively. GOF mutation sites are shown in blue.
Fig. (3)
Fig. (3)
Names and structures of BK, SK, and IK channel modulators.

Similar articles

Cited by

References

    1. Nappi P., Miceli F., Soldovieri M.V., Ambrosino P., Barrese V., Taglialatela M. Epileptic channelopathies caused by neuronal Kv7 (KCNQ) channel dysfunction. Pflugers Arch. 2020;472(7):881–898. doi: 10.1007/s00424-020-02404-2. - DOI - PubMed
    1. Niday Z., Tzingounis A.V. Potassium channel gain of function in epilepsy: An unresolved paradox. Neuroscientist. 2018;24(4):368–380. doi: 10.1177/1073858418763752. - DOI - PMC - PubMed
    1. Kole M.H.P., Stuart G.J. Signal processing in the axon initial segment. Neuron. 2012;73(2):235–247. doi: 10.1016/j.neuron.2012.01.007. - DOI - PubMed
    1. Gutman G.A., Chandy K.G., Grissmer S., Lazdunski M., Mckinnon D., Pardo L.A., Robertson G.A., Rudy B., Sanguinetti M.C., Stühmer W., Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol. Rev. 2005;57(4):473–508. doi: 10.1124/pr.57.4.10. - DOI - PubMed
    1. Barcia G., Fleming M.R., Deligniere A., Gazula V.R., Brown M.R., Langouet M., Chen H., Kronengold J., Abhyankar A., Cilio R., Nitschke P., Kaminska A., Boddaert N., Casanova J.L., Desguerre I., Munnich A., Dulac O., Kaczmarek L.K., Colleaux L., Nabbout R. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat. Genet. 2012;44(11):1255–1259. doi: 10.1038/ng.2441. - DOI - PMC - PubMed

MeSH terms

Substances